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ABSTRACT Control and eradication of foot-and-mouth disease (FMD) are impeded
by the existence of a persistent, subclinical phase of infection in ruminants; animals
with this status are referred to as carriers. However, the epidemiological signiﬁcance
of these FMD virus (FMDV) carriers is uncertain. In the current investigation, the con-
tagion associated with FMDV carrier cattle was investigated by exposure of suscepti-
ble cattle and pigs to oropharyngeal ﬂuid (OPF) samples or tissues harvested from
persistently infected cattle. Naive cattle were inoculated through intranasopharyn-
geal deposition of unprocessed OPF samples that had been collected from FMDV
carriers at 30 days postinfection. These inoculated cattle developed clinical FMD, and
the severity of disease they developed was similar to that of animals that had been
infected with a high-titer inoculum. In contrast, pigs exposed via intraoropharyngeal
inoculation of the same OPF samples or via ingestion of nasopharyngeal tissues har-
vested from the same cohort of persistently infected cattle did not develop FMD.
These ﬁndings indicate that there is demonstrable contagion associated with FMDV
carrier cattle despite the lack of evidence for transmission by direct contact. The
ﬁndings presented herein provide novel information that should be considered for
FMD risk mitigation strategies.
IMPORTANCE Foot-and-mouth disease (FMD) is a viral disease of livestock with sub-
stantial impact on agricultural production and subsistence farming on a global scale.
Control of FMD is impeded by the existence of a prolonged asymptomatic carrier
phase during which infected cattle shed low quantities of infectious virus in oropha-
ryngeal ﬂuid (OPF) for months to years after infection. The epidemiological signiﬁ-
cance of FMD virus (FMDV) carriers is unresolved. However, the existence of the
FMDV carrier state has substantial impact on international trade in animal products.
The current investigation demonstrated that transfer of OPF from persistently in-
fected FMDV carrier cattle to naive cattle led to fulminant clinical FMD. It was thus
demonstrated that, although the risk for disease transmission under natural condi-
tions is considered to be low, there is detectable contagion associated with FMDV
carrier cattle. This ﬁnding is important for optimization of FMD risk mitigation strate-
gies.
KEYWORDS FMDV, carrier, cow, foot-and-mouth disease, foot-and-mouth disease
virus, risk, transmission, virus
Foot-and-mouth disease (FMD), caused by infection with FMD virus (FMDV; familyPicornaviridae, genus Aphthovirus), is an economically important disease of livestock
(1, 2). Large regions of the developed world, including Europe, North America, and
Australia, are kept free of FMD through strict regulations on the importation of animals
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and related products. However, the disease is still endemic in most of Africa and Asia
(3–5). FMDV can infect a wide range of cloven-hoofed animals and can cause severe
disease in domestic ruminants and pigs (6, 7). The endemic presence of FMD is
problematic, as it prevents access to international markets for trade in animal products.
Additionally, measures required for disease control, including repeated vaccination
campaigns and control of animal movements, are economically and logistically chal-
lenging in many affected regions. In countries that are normally free of FMD, incursions
of the disease cause major disruptions in agricultural production and severe losses in
revenue due to interrupted trade (8–11). Control and eradication of FMD are further
impeded by the existence of a subclinical persistent phase of infection in ruminant
species (7, 12). This FMDV carrier state has traditionally been deﬁned by detection of
infectious FMDV in oropharyngeal ﬂuid (OPF) more than 28 days postinfection (dpi),
and it is reported to occur in 50% of infected cattle (12). However, recent work has
demonstrated that carriers may be identiﬁed as early as 15 dpi in vaccinated cattle and
21 dpi in cattle that were not vaccinated (13). Persistent FMDV infection occurs in both
vaccinated and naive cattle, regardless of the occurrence of clinical disease (14, 15). This
is of particular concern in relation to the use of emergency vaccination to control FMD
outbreaks in regions that are normally free of FMD, as infection in vaccinated animals
may go unnoticed.
Cattle are highly sensitive to FMDV infection via the respiratory route, and the site
of initial virus replication has been localized to speciﬁc regions of epithelium of the
nasopharyngeal mucosa that contain mucosa-associated lymphoid tissue (MALT) (16–
18). The clinical phase of disease includes fever, transient viremia, and the occurrence
of characteristic vesicular lesions in and around the mouth, on the feet, and in other
areas of nonhaired skin (1). Affected animals may develop severe lameness; in addition,
both milk yield and growth rates may be reduced. Mortality rates are low in adult
animals, which generally recover from the clinical phase of FMD within approximately
2 weeks. Persistent FMDV infection in cattle has, similar to early infection, also been
localized to lymphoid-associated epithelium of the nasopharynx (13, 19). During the
persistent phase of infection, FMDV can be detected in nasopharyngeal tissues and in
OPF sampled using a probang (sputum) cup (20), but it is usually not detected in oral
or nasal swab samples (13, 21, 22).
The existence of the FMDV carrier state has had a profound impact upon legislation
concerning international trade in animal products (6, 23). However, there is still
uncertainty regarding the actual level of risk associated with FMDV carriers as well as
their potential role in the ecology of FMDV in regions where FMD is endemic (24, 25).
Historical records have reported FMD outbreaks that were believed to have been
seeded by transmission of FMDV from a persistently infected carrier to a susceptible
animal (14, 24). However, multiple, small-scale, experimental investigations have failed
to demonstrate transmission of FMDV from persistently infected carrier cattle to
contact-exposed sentinels (22, 26, 27). A meta-analysis of experimental attempts to
transmit FMDV from carrier cattle to naive cattle or pigs demonstrated that transmis-
sion had occurred only once among 26 published attempts (28). The original record
from that transmission study reported conﬁrmed seroconversion, without clinical signs
of FMD, in two pigs after 75 days of contact exposure to carrier cattle (29). It has been
speculated that the apparent lack of contagion associated with FMDV carrier cattle may
be due to neutralization of virus shed in OPF by secreted anti-FMDV IgA. This theory is
supported by a demonstrated increase in infectivity in tissue culture of OPF samples
that have been treated with a ﬂuorocarbon compound to dissociate immunoglobulin-
bound virus (13, 30). There is experimental evidence that supports transmission from
persistently infected African buffalo (Syncerus caffer) to in-contact cattle (31, 32).
Additionally, in an experimental investigation from 1968, it was shown that it is possible
to infect naive cattle by intrapharyngeal inoculation of OPF samples harvested from
FMDV carriers (33). However, the published details of the experiment lack explicit
details.
The objective of this current study was to investigate the infectivity of unprocessed
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OPF samples and pharyngeal tissues harvested from persistently infected FMDV carri-
ers. For this purpose, naive calves and pigs were exposed to OPF samples harvested
from FMDV carriers using simulated-natural inoculation systems. Additionally, samples
of nasopharyngeal mucosal tissues harvested from the same cohort of FMDV carriers
were macerated and fed to naive pigs. The ﬁndings presented herein demonstrate that
OPF from FMDV carrier cattle is indeed infectious and may, under speciﬁc conditions,
cause disease in susceptible cattle. Lack of disease in exposed pigs is consistent with
previous reports (34) suggesting that higher quantities of virus may be required to
infect pigs with FMDV via natural exposure routes.
RESULTS
Animal experiments. The experiments reported herein consisted of three distinct
phases. Phase I included nine steers that were infected with a high-titer FMDV inoculum
and monitored to the persistent phase of infection. Experimental phase II consisted of
eight steers that were challenged by intranasopharyngeal inoculation of oropharyngeal
ﬂuid (OPF) samples that had been harvested from the persistently infected steers of
phase I at 30 days postinfection (dpi). Phase III consisted of two groups of ﬁve pigs; one
group was challenged by intraoropharyngeal inoculation of the pooled OPF obtained
from the phase I cattle, and the other group was fed macerated nasopharyngeal tissues
from the same persistently infected cattle.
Clinical progression and infection dynamics in phase I cattle. The main purpose
of the ﬁrst phase of the experiment was to produce carrier cattle and harvest appro-
priate material for inoculation of cattle and pigs in phases II and III. Following intrana-
sopharyngeal (INP) deposition of FMDV A24 Cruzeiro, all nine animals in phase I of the
study developed clinical FMD, consistent with previous investigations using the same
virus strain, dose, and exposure route (13, 18, 35). Vesicular lesions were observed in the
mouth as well as on one or more feet of all animals, with initial detection of lesions
occurring between 3 to 6 dpi (Fig. 1). Four animals in phase I reached the maximum
lesion score, with lesions in the mouth and on all four feet. The remaining ﬁve animals
had one or more feet without lesions (Fig. 1). Viremia, deﬁned as detection of FMDV
RNA in serum, was apparent in all nine animals and lasted for 2 to 5 days. Abundant
quantities of FMDV RNA were detected in nasal ﬂuids throughout the clinical phase of
infection. Nasal FMDV detection ceased between 7 and 10 dpi. Low quantities of FMDV
RNA were detected in at least two OPF samples in all animals. However, two animals
(animals 02 and 09) had two or more FMDV RNA-negative OPF samples, including the
sample harvested at 28 dpi (Fig. 1). Therefore, OPF from these two animals was not
included in the pooled inoculum that was harvested at 30 dpi and used for challenge
of animals in phase II. The persistently infected animals of phase I were euthanized for
tissue harvest at 31 dpi.
Infectivity of OPF inoculum and pooled tissue macerate. The titer of FMDV in the
unprocessed, pooled OPF (i.e., the material that was used to challenge cattle and pigs
in phases II and III, respectively) was 101 50% tissue culture infectious doses (TCID50) per
ml on LFBK-v6 cells and below the detection level on BHK-21 cells (Table 1).
Trichlorotriﬂuoroethane (TTE) treatment of the OPF increased the titer to 102.5
TCID50/ml on LFBK-v6 cells, but the infectivity was still below the detection limit
when using BHK-21 cells (Table 1). All titrations of the nasopharyngeal tissue macerate
were below detection limits for both cell lines. However, infectious virus was isolated
when a higher volume (1 ml) of the same tissue macerate was inoculated onto
LFBK-v6 cells in unﬁltered form (Table 1). Calculating the challenge doses using the
titer of the non-TTE-treated OPF derived from the highly sensitive LFBK-v6 cells
indicated that cattle in phase II received a dose of 102 TCID50, and the pigs in phase III
that were challenged by intraoropharyngeal (IOP) inoculation received 5  101 TCID50.
Clinical progression and infection dynamics in phase II cattle. The second phase
of the experiment included eight cattle that were challenged by INP deposition of 10 ml
of pooled OPF that had been harvested at 30 dpi from seven phase I animals that had
been identiﬁed as being persistently infected carriers. The ﬁrst sign of FMD in the phase
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II cohort consisted of a large vesicle on the tongue of animal 13 at 4 dpi (Fig. 2). On the
subsequent day, an interdigital cleft lesion was detected in this same animal, and oral
vesicles were observed in ﬁve additional animals (Fig. 2). The remaining two cattle had
developed oral lesions by day 6 and 7, respectively. Seven out of the eight animals
developed lesions on one or more feet subsequent to the initial oral lesions. All animals
became viremic, although FMDV RNA was detected in only one serum sample from
animal 17. High quantities of FMDV RNA were detected in nasal secretions from all
eight cattle starting from 2 to 4 dpi until 7 to 10 dpi (Fig. 2). The severity and
progression of clinical FMD were similar to those observed in phase I cattle.
Clinical monitoring and infection dynamics in phase III pigs. The pigs in the third
phase of the study were challenged by either intraoropharyngeal deposition (n  5) of
FIG 1 FMDV infection dynamics in cattle in phase I of the study. Detection of FMDV RNA by RT-qPCR in nasal swabs and serum and oropharyngeal ﬂuid (OPF)
samples collected from cattle infected with 105 TCID50 of FMDV A24 Cruzeiro following intranasopharyngeal inoculation. Time (in days postinoculation) is shown
on the x axes, CT values are shown on the left-hand y axes, and lesion scores are shown on the right-hand y axes. The blue shaded area represents cumulative
lesion score, which was recorded up to 10 days postinfection (dpi). OPF was collected twice weekly from 14 dpi. Pooled OPF used for challenge of cattle in
experimental phase II and pigs in phase III was harvested at 30 dpi, from all animals except animals 02 and 09 (the FMDV carrier status of these two animals
was undetermined).
TABLE 1 FMDV detection in pooled OPF and nasopharyngeal tissues from persistently infected carriers
Sample CT value by FMDV RT-qPCR FMDV isolation in LFBK-v6 cellsa,b
FMDV titer (TCID50/ml) inb:
BHK-21 cells LFBK-v6 cells
Unprocessed TTE-treated Unprocessed TTE-treated
OPF 31.8 Pos Neg Neg 101 102.5
Tissue 32.0 Pos Neg Neg Neg Neg
aVirus isolation on LFBK-v6 cells in T25 ﬂask using unprocessed and unﬁltered material.
bPos, positive (observed cytopathic effect [CPE] with FMDV replication conﬁrmed by RT-qPCR); Neg, negative.
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the same pooled OPF as was used to challenge cattle in phase II or by feeding
macerated nasopharyngeal tissues (n  5) harvested from the persistently infected
carriers of phase I at 31 dpi. There were no signs of FMD in any of the pigs included in
the third phase of the experiment. Similarly, FMDV RNA was not detected in any
oropharyngeal (OP) swabs or serum samples (not shown), and no antibodies against
FMDV were detected in sera from each of these pigs collected at 14 dpi (not shown).
FMDV sequence analysis. In order to assess the region speciﬁcity of genomic
changes during the course of these studies, near-complete FMDV genome sequences
were acquired from the original virus inoculum, as well as from nasal swab samples
obtained during the clinical phase of infection from one calf from experimental phase
I and from one calf from phase II (not shown). The majority of the observed changes
within the genome occurred within the VP1 coding region. On this basis, further
genomic analysis was focused upon the VP1-2A coding sequence in FMDV RNA derived
from nasal swab samples from all animals in phase I and almost all animals from phase
II (not including one animal). Samples for sequence analysis ranged from 3 to 4 dpi for
FIG 2 FMDV infection dynamics in cattle in phase II of the study. Detection of FMDV RNA by RT-qPCR in nasal swabs and serum samples in cattle infected
through intranasopharyngeal inoculation of pooled OPF obtained from cattle in experimental phase I at 30 dpi. The blue shaded area represents cumulative
lesion score, which was recorded up to 10 days postinfection (dpi). The challenge dose was determined to have been 102 TCID50 per animal.
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phase I and 6 to 7 dpi for phase II. Speciﬁc samples were selected based on the
presence of high levels of FMDV RNA (as judged by a low threshold cycle [CT] value in
real-time quantitative PCR [RT-qPCR] assays) and corresponded to the peak of clinical
FMD for both phase I animals and phase II animals. Nonsynonymous changes in the
coding sequence were found predominantly at amino acid residues 133, 144, and 147
(Fig. 3) of VP1 which includes the integrin-binding motif (RGD) within the G-H loop.
While the original inoculum and all phase I samples included amino acid sequences
RSGDM or RSGDT at this site, all samples from the phase II animals were either RRGDM
or RRGDT (Fig. 3). Due to low RNA content, it was not possible to obtain the VP1 coding
sequence from the pooled OPF inoculum used for challenge of phase II cattle without
one passage of the virus in tissue culture. However, the passaged phase II inoculum had
a sequence encoding RRGDT at the speciﬁed site, indicating that the S-to-R substitution
at residue 144 had occurred during the later stages of infection of the phase I cattle.
Additionally, the sequences obtained from the phase II samples suggested that infec-
tion of this group was seeded by at least two major viral variants; one with methionine
(M) at residues 133 and 147 and another with threonine (T) at both of these sites. The
two variants at residue 147 had been present in different cattle in phase I. This
suggested that virus from at least two different cattle from phase I initiated infection
in phase II.
DISCUSSION
Although the FMDV carrier state was ﬁrst described in cattle almost 60 years ago
(36), the epidemiological signiﬁcance of FMDV carriers remains undetermined and
controversial. Although numerous reports have characterized the carrier state under
natural and laboratory conditions, the crucial issue of whether carrier cattle pose a
FIG 3 Nucleotide sequences encoding part of the VP1 capsid protein of FMDVs derived from infected cattle in phase I and phase II of the study.
Partial VP1 coding sequence obtained from nasal swab samples collected during the clinical phase of FMD from cattle of experimental phases
I (animal identiﬁers [IDs] 01 to 09) at 3 or 4 dpi and phase II (animal IDs 10 to 17) at 6 or 7 dpi. The top row (*A24CruzIn for A24 Cruzeiro given
INP) represents the consensus sequence of the inoculum used to infect cattle in phase I. The middle row (**A24CruzP1) is the consensus sequence
of the pooled OPF inoculum (as determined after a single passage in cell culture; see text) that was used to infect cattle in phase II. Nucleotide
changes and the corresponding amino acid substitutions are marked using the same color code. The variations in coding sequence suggest that
the inoculums used for both phase I and II consisted of heterogeneous viral populations. Additionally, the sequences obtained from phase II
animals suggest that infection of this group of animals was seeded by at least two different virus populations, as the samples from animals 10
and 13 are distinct from the remaining samples at amino acid residues 133 and 147 of VP1. Y  mixture of C and T (pyrimidines). AA seq, amino
acid sequence; AA res., amino acid residue.
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signiﬁcant risk of contagion remains incompletely resolved. Despite a lack of substan-
tiated experimental evidence of transmission from FMDV carrier cattle (28), the FMDV
carrier state has had an impact upon the regulation of global trade in animal products
(24, 37). The objective of this current investigation was to use recent knowledge about
the initial and persistent sites of virus replication (13, 18) to investigate the potential
risk of disease transmission associated with biological materials (OPF samples and
tissues) from persistently infected FMDV carrier cattle.
Although the manner of transfer of OPF samples to naive cattle used herein could
not occur under natural conditions, the ﬁnding of transmission of FMD from unpro-
cessed OPF samples from carrier cattle indicates that the potential risk of disease
outbreaks being initiated from these animals is real and cannot be discounted. Naive
cattle and pigs were exposed to OPF samples from persistently infected carriers via
direct intranasopharyngeal (INP) (cattle) or intraoropharyngeal (IOP) (pigs) deposition.
These challenge systems have been developed to simulate natural, species-speciﬁc,
exposure conditions while maintaining control of the dose and timing of virus chal-
lenge (38, 39). These challenge systems are needle-free inoculation systems that do not
breach the mucosal barrier but rely on natural mechanisms of virus entry into suscep-
tible cells at the documented primary infection sites. Additionally, one group of pigs
was fed nasopharyngeal tissues from FMDV carriers to test the hypothesis that feeding
pigs offal from persistently infected animals may constitute a risk for initiation of FMD
outbreaks.
Titrations of the pooled OPF on highly sensitive LFBK-v6 cells suggested that
the INP-challenged cattle had each received a total dose of 102 TCID50, whereas the
IOP-challenged pigs had each received a dose of 5  101 TCID50. However, the
infectivity of the pooled OPF was below the detection limit when titration was
attempted using the cell line most commonly used for isolation of FMDV (BHK-21
cells). The small (twofold) difference in inoculation dose between cattle and pigs
was purely a practical consequence of not being able to deposit a larger volume of
ﬂuid onto the porcine tonsil of the soft palate. It was not possible to measure an
infectivity titer in the macerated tissue that was fed to the pigs in experimental
phase III. However, RT-qPCR analysis and successful virus isolation on LFBK-v6
cells indicated the presence of low quantities of infectious FMDV in this material.
Viral sequence analysis was utilized to determine whether multiple animals had
been infected by the phase II inoculum, as opposed to a single animal being infected
by inoculation and subsequently transmitting the disease to the other phase II animals.
The predicted VP1 amino acid sequence encoded by the FMDV RNA isolated from nasal
swab samples obtained from the clinical phase of cattle in phase II indicated that
infection of that group of cattle was seeded by at least two distinct viral variants.
Speciﬁcally, the viral sequence obtained from animal 13, which had developed clinical
FMD 1 day earlier than the majority of animals of the group, was similar to only one
other sample obtained from that group (animal 10). This suggests that animals 12, 14,
15, 16, and 17 were not infected by animal 13, but rather through at least one
additional distinct primary infection directly from the inoculum. Interestingly, all se-
quences obtained from phase II samples differed from the phase I samples within the
integrin-binding region of the G-H loop (RSGD in phase I samples versus RRGD in phase
II samples). However, since only samples from the clinical phase of infection were
included in this analysis, it is likely that this substitution had occurred during the later
stages of infection of the phase I animals, as suggested by the sequence obtained from
the pooled OPF inoculum (Fig. 3).
The use of OPF and the simulated natural INP system in this study had advantages
but also intrinsic limitations. Under natural conditions, the probability that a sufﬁcient
quantity of FMDV shed from a carrier animal would reach the susceptible cells within
the nasopharynx of a naive animal is likely very small. However, the successful trans-
mission under these experimental conditions substantiates the perceived risk of con-
tagion associated with persistently infected FMDV carrier cattle. Furthermore, these
Transmission of FMD from Persistently Infected Carriers
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ﬁndings conﬁrm that the infectious dose of FMDV required to infect cattle through
nasopharyngeal exposure is very low.
There has been speculation on the mechanisms responsible for the low infectious-
ness of FMDV carrier cattle, but the mechanisms have not been deﬁnitively elucidated.
It has been postulated that FMDV in OPF from persistently infected animals may be
shed either as immunoglobulin-bound (cell-free) virus or within detached cells or
cellular debris (2). Oropharyngeal ﬂuid samples from FMDV carriers contain secreted
anti-FMDV IgA (13, 40, 41), which may decrease infectivity. Furthermore, it has been
demonstrated that the apparent infectivity of OPF samples increases substantially for
tissue culture cells if these samples are pretreated with a ﬂuorocarbon compound
(1,1,2-trichlorotriﬂuoroethane or trichlorotriﬂuoroethane [TTE]), which is believed to
dissociate immunoglobulins bound to FMDV (30, 42). The advantages of using TTE
treatment of OPF samples prior to virus isolation have been utilized in multiple
large-scale investigations (13, 19, 43, 44) and were conﬁrmed in this investigation by an
increased titer measured in the TTE-treated OPF. However, it is also possible that the
increased virus titers detected after TTE treatment of OPF may be caused by disruption
of cellular membranes and thereby release of virus from cells or cellular debris present
within the OPF. Shedding of persistent FMDV in association with sloughing of super-
ﬁcial nasopharyngeal epithelial cells is consistent with ﬁndings from investigations
using immunomicroscopy in our laboratory (13). Additionally, previous in vitro inves-
tigations have suggested that FMDV may be released from infected cells within
“cytoplasmic blebs” (45). This may be similar to the nonlytic cellular escape mechanisms
that have been described for other picornaviruses (46). Speciﬁcally, hepatitis A virus and
some members of the Enterovirus genus have been reported to be released from
infected cells in a “quasi-enveloped” state within membranous vesicles (47–49). To our
knowledge, such nonlytic cellular escape of FMDV has not yet been described in vivo.
Although the mechanism of shedding of FMDV into OPF in persistently infected
animals is not known, the possible release of virus within membranous compartments
could potentially prevent immediate binding of secreted IgA to FMDV and thus protect
the infectivity of shed virus.
The pigs exposed to the OPF from the carrier cattle in this investigation did not
become infected. This is in agreement with previous reports that have concluded that
higher infectious doses are required to initiate FMD in this species (2, 34). Feeding
unprocessed food waste to pigs has been associated with initiation of FMD epidemics
(50). However, the current ﬁndings suggest that the amounts of FMDV present in OPF
or nasopharyngeal tissues of FMDV carriers may not be sufﬁcient for disease dissemi-
nation to pigs to occur readily via this route. Further investigations are necessary to
determine a minimum infectious dose to infect pigs via oropharyngeal exposure.
Conclusions. This current investigation demonstrated that it is possible to transmit
FMDV from persistently infected cattle to naive recipient cattle via mechanical transfer
of unprocessed oropharyngeal ﬂuid. Pigs exposed to the same material, under similar
conditions, did not develop FMD, which suggests that a higher infectious dose and/or
distinct mechanisms are required to infect this species by this route. These results
contribute to improved understanding of the FMDV carrier state and provide novel
information that is relevant for FMD risk analyses.
MATERIALS AND METHODS
Virus. The virus used for this investigation was an isolate of FMDV strain A24 Cruzeiro that had been
passaged twice in cattle as used previously (13).
Authentication of cell lines. The cell lines used for virus isolation were LFBK-v6 (51), which are
porcine kidney cells transfected with a bovine integrin receptor, and BHK-21 cells originally obtained
from ATCC (Manassas, VA, USA). Species speciﬁcity and absence of cross-contamination of cell lines were
conﬁrmed by validated conventional PCR assays detecting DNA from pig, cow, hamster, and monkey,
corresponding to the species origin of cell lines routinely used in the laboratory.
Animals. All animal experiments were performed in the CL3Ag FMDV research facility on Lindholm
Island, which is part of the National Veterinary Institute of the Technical University of Denmark (DTU). This
study was conducted with approval from the Danish Animal Experimentation Inspectorate (license
201415-0201-00173) in accordance with Danish and European Union (EU) legislation (Consolidation Act
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474 15/05/2014 and EU Directive 2010/63/EU). Cattle were Holstein bull calves weighing approximately
150 to 200 kg upon arrival. Pigs were conventionally bred Landrace/Yorkshire mixed males and females
weighing approximately 20 kg at delivery. All animals were allowed 1 week of acclimatization in the
facility before the start of the experiments.
Study design. Phases I and II of the study were carried out sequentially, using separate isolation
units, while phase III was performed several weeks later after cleaning, disinfection, and fumigation of the
unit.
Phase I. The ﬁrst phase of the experiments included nine cattle that were inoculated with 105
infectious doses (titrated in bovine tongue epithelium) of FMDV A24 via intranasopharyngeal (INP)
inoculation as previously described (38). Brieﬂy, cattle were sedated and placed in sternal recumbency,
and the virus inoculum (2 ml), diluted in minimal essential medium (MEM) with 25 mM HEPES, was
deposited within the nasopharynx using a ﬂexible 30-cm catheter. The cattle in the ﬁrst phase of the
study were monitored for 30 days postinfection (dpi). Oropharyngeal ﬂuid (OPF) samples for challenge
of cattle and pigs in phases II and III were collected at 30 dpi, and tissues for challenge of pigs in phase
III were harvested at 31 dpi immediately after euthanasia. Nasopharyngeal tissue samples for feeding to
pigs consisted of the dorsal surface of the soft palate and the dorsal surface of the nasopharynx as
previously described (13, 16). Tissue samples were macerated using forceps and scissors to facilitate
feeding to pigs in phase III. Clinical monitoring and sample collection were carried out as described
below.
Phase II. The second phase of the experiment included eight cattle that were subjected to INP
inoculation as described above, but with each animal receiving 10 ml of pooled OPF that had been
harvested at 30 dpi from seven phase I animals that had been identiﬁed as being persistently infected
carriers. Prior to inoculation of phase II animals, the pooled OPF was homogenized using a 16-gauge
metal cannula attached to a 50-ml syringe in order to disrupt mucous and potential epithelium within
the sample. There was no further processing or freezing of this material prior to inoculation of the phase
II cattle. Challenge of phase II cattle (0 dpi) was performed on the same day as the OPF samples were
harvested from phase I animals (30 dpi). Animals in this second phase of the experiment were monitored
for a further 14 days.
Phase III. The third phase of the investigation included two groups of ﬁve pigs each. The pigs in the
ﬁrst group were inoculated with OPF from the phase I carrier cattle (stored at80°C following collection)
by intraoropharyngeal (IOP) inoculation as previously described (39). Brieﬂy, sedated pigs were placed in
dorsal recumbency, and the inoculum (5 ml) was deposited onto the surface of the tonsil of the soft
palate using a blunt-ended metal cannula. Pigs were kept on their backs for approximately 1 min before
they were placed in sternal position and left to recover from the sedation. The pigs in the second group
were each fed approximately 45 g of nasopharyngeal tissue harvested from the phase I cattle. The
macerated tissues were mixed with a small amount of the pig’s standard feed, and each pig received the
measured ration in a separate feeding bucket. Both groups of pigs were monitored for the following
14 days.
Clinical monitoring and sample collection. Samples collected to evaluate infection dynamics in
cattle were nasal swabs and blood and OPF samples. Nasal swabs were collected using tampons inserted
into each nostril, and blood samples were collected through jugular venipuncture. Blood samples and
tampons were centrifuged at 2,075  g for 10 min to harvest serum and nasal ﬂuid, respectively. Blood
samples were collected daily from 0 to 10 dpi, and once per week thereafter. Nasal swabs were collected
daily from 0 to 10 dpi and twice per week thereafter. OPF was collected using a probang cup. Probang
sampling of phase I animals was conducted twice weekly from 14 to 28 dpi, with an additional ﬁnal
sampling at 30 dpi in order to harvest OPF for challenge of phase II animals. The OPF was diluted with
an equal volume of MEM with 25 mM HEPES, except for the 30 dpi sample for which the amount of
added medium was reduced to half (giving a 2:1 ratio). OPF samples were homogenized using a syringe
and cannula as described above. FMDV carrier status of phase I animals was determined on the basis of
consistent detection (by real-time quantitative PCR [RT-qPCR]) of FMDV RNA in OPF from 14 dpi to 28 dpi.
At 30 dpi, OPF samples were collected only from the seven cattle that had been identiﬁed as FMDV
carriers.
Samples collected from pigs were whole blood and oropharyngeal (OP) swabs as previously
described (39). The OP swab samples were harvested using a large cotton swab applied to the tonsil of
the soft palate and subsequently immersed in MEM (2 ml) with 25 mM HEPES. Swabs and blood samples
were centrifuged as described above to retrieve the OPF and serum. Swabs were collected daily from 0
to 10 dpi and again at 14 dpi. Blood samples were collected on 0, 2, 3, 4, 6, 8, 10, and 14 dpi.
Daily clinical examinations of both cattle and pigs included monitoring for any signs of FMD, such as
fever, lameness, and vesicular lesions. The occurrence and progression of clinical FMD were recorded
using a cumulative lesion score for which any lesion on the head contributed 1 point and foot lesions
contributed 1 point per affected foot, giving a maximum score of 5. For cattle, the head and oral cavity
were inspected daily from 0 to 10 dpi. Feet were inspected twice weekly in sedated cattle (0, 3, 6 and
10 dpi for phase I cattle and 0, 3, 5, 7, and 10 dpi for phase II cattle). For pigs, the head and feet were
examined daily from 0 to 10 dpi and again after euthanasia at 14 dpi.
FMDV RNA detection. Total RNA was extracted from serum, nasal ﬂuid, and OPF samples using a
MagNA Pure LC total nucleic acid isolation kit (product no. 03038505001; Roche) with an automated
robotic workstation (Roche), according to the manufacturer’s instructions. The level of FMDV RNA in
serum and nasal ﬂuid samples was determined using a one-step quantitative RT-PCR assay targeting the
3D-coding region of the FMDV genome (52) as modiﬁed by Vandenbussche et al. (53). OPF samples were
analyzed using similar primers and probes, but in a two-step assay. Brieﬂy, cDNA was produced using
Transmission of FMD from Persistently Infected Carriers
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reverse transcriptase (TaqMan reverse transcriptase; Applied Biosystems) with random hexamer primers
(Roche). The quantitative PCR was performed using AmpliTaq (Applied Biosystems) using the primers and
probes described by Callahan et al. (52).
Quantitation of infectivity in OPF and tissue macerate. The in vitro infectivity of the OPF and
nasopharyngeal tissue samples obtained from the seven persistently infected carriers at 30 dpi was
evaluated through titration on BHK-21 and LFBK-v6 cells (51) as previously described (17). Two
aliquots of 30 mg of tissue macerate were thawed, MEM (900 l) and two steel beads (catalog no. 69989;
Qiagen) were added to each aliquot, and the samples were homogenized using a TissueLyser bead
beater (Qiagen) (2 min; frequency, 22/s). The processed macerates were pooled and clariﬁed through
centrifugation at 1,000  g for 2 min at 4°C. For both the processed tissue macerate and the pooled OPF
sample, one aliquot (1 ml) was treated with 1,1,2-trichlorotriﬂuoroethane (TTE) for dissociation of
immunocomplex-bound virus as previously described (54). All four sample aliquots (TTE-treated and
nontreated OPF and processed tissue macerate) were cleared of debris and potential bacterial contam-
ination by centrifugation through Spin-X ﬁlter columns (pore size, 0.45 m; catalog no. 8163; Costar) and
were subsequently inoculated onto the two different cell types. Calculations of infectivity (as 50% tissue
culture infectious doses [TCID50] per milliliter) were performed by standard methods (55). An additional
attempt to isolate FMDV from the tissue macerate was performed by inoculating T25 ﬂasks of both
LFBK-v6 and BHK-21 cells with 1 ml of non-TTE-treated and nonﬁltered macerate. All supernatants
were analyzed by RT-qPCR to determine the occurrence of FMDV replication.
Detection of anti-FMDV antibodies in serum. Serum samples obtained at 0 and 14 dpi from the
pigs in experimental phase III were analyzed for the presence of anti-FMDV antibodies using a solid-
phase blocking enzyme-linked immunosorbent assay (ELISA) as previously described (56).
FMDV sequence assembly and analysis. RNA was extracted from nasal swab samples from
individual calves (collected on preselected days) and also from the FMDV A24 inoculum using the MagNA
Pure system (Roche) as described by the manufacturer. The cDNA synthesis was carried out using
Ready-To-Go You-Prime First-Strand beads (GE Healthcare Life Sciences, Uppsala, Sweden) with a mixture
of random hexamer primers [pd(N)6] and oligo(dT). The cDNA was diluted to 150 l from which an
aliquot (5 l) was used to amplify the VP1 coding region using primers 10-PPN6 (5=-TAGCGCCGGCAAA
GACTTTGA) and 1-OPN20 (5=-GACATGTCCTCCTGCATCTG). The products (ca. 810 bp) were puriﬁed using
a QIAquick gel extraction and puriﬁcation kit (Qiagen, Hilden, Germany) and quantiﬁed using a Nanodrop
1000 spectrophotometer (Fisher Scientiﬁc, Waltham, MA, USA). Sequencing of the PCR products was
TABLE 2 Primers used for RT-PCRs and sequencing
Primer Primer sequence (5=–3’)a Orientation Location (nt)b
8-APN35 GAGAAAXGGGACGTCXGCGC Forward 522
8-APN2 GTCXCCTATTCAGGCXTAGAAG Reverse 990
8-APN3 GGCTAAGGATGCCCTTCAG Forward 894
9-XPN18 TTXGAXAACCAXTCXTTXTTXTGXGTGTT Reverse 1832
14-CPN63 CCGTTGGAGGTGACACACG Reverse 1503
14-CPN7 ATGCCATCAGTGGAGGCTCC Forward 1773
14-CPN6 GTCCAACAGGTTGGTGAAGC Reverse 2679
14-CPN5 ATGGCAAGGTGTACAACCCG Forward 2637
11-FPN35 GAARGGCCCRGGGTTGGAC Reverse 3898
14-CPN61 GGAGGCGCAACTCAAAGTC Reverse 3185
14-CPN3 TACAACAAGGCACCATTCACG Forward 3542
11-SPN3 ACACTGTCGCCAGCACACG Reverse 3593
14-CPN4 CCAGACCGCTGTTGGCAATAG Forward 3783
8-APN45 GGAAGAAACTCGAGGCGAC Reverse 4316
8-APN22 AAGGACCCXGTCCTTGTGGC Forward 4151
1-XPN28 GTTGTAGCCGTCXAAGTGGTC Reverse 4808
8-APN46 TGGTCGTTTGCCTCCGTGG Forward 4683
8-APN87 CTCAAAGAATTCAATTGCTGC Reverse 5387
8-APN13 GCXCTTCTXAACGGXATGGC Forward 5171
8-APN68 GGGTCCTTCAGCTGGTGG Reverse 5774
8-APN113 CGCGAXACTCGCAAGAGAC Forward 5555
9-XPN11 AGCATGTCCTGTCCTTTTACT Reverse 6223
14-CPN2 CCATTTGCTGTGCTACTGGA Forward 6084
8-APN114 CAGGGTTGAACACACCGTG Reverse 6716
9-XPN2 AATGAAGGCACACXTXGAXCCXGA Forward 6601
14-CPN1 AGGGTTACAACCGACCGCG Reverse 7276
8-APN17 CTGAAGGACGAXXTXCGXCC Forward 7124
8-APN52 GGAXTGACCAAGAACAAAACC Reverse 7754
9-XPN23 TGGACACXTACACCATGATCTC Forward 7620
NVT27 TTTTTTTTTTTTTTTTTTTTTTTTTTTVN Reverse 8140
aX  inosine.
bThe primer locations are based on the sequence of FMDV A24 Cruzeiro (accession no. AY593768.1). For
forward primers, the 5=-terminal nucleotide (nt) is used, while for the reverse primers, the position of the nt
that is complementary to the 3= nt of the primer is given.
Arzt et al.
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performed using a BigDye Terminator v 3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA,
USA), using the same primers as used in the PCRs, according to the manufacturer’s instructions, and ran
on an automated DNA sequencer (ABI PRISM 3730 DNA analyzer; Applied Biosystems, Foster City, CA,
USA). The resulting consensus sequences were compared to others using MUSCLE (https://www.ebi.ac
.uk/Tools/msa/muscle/) and translated into amino acid sequences using ExPASy (https://web.expasy.org/
cgi-bin/translate/dna_aa). Near-full-length genome sequences, from selected samples, were assembled
using Seqman Pro 14 based on the production and sequencing of 15 separate PCR products, using
primers (Table 2) to produce overlapping amplicons.
Accession number(s). The sequence of the inoculum used to infect the animals, and to which all
other sequences were compared, is available at GenBank under accession no. MH746921.
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